Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm plus NSCLC and Acquired T790M: The Real-World UpSwinG study

被引：0
|
作者：
Popat, S. [1 ,2 ]
Jung, H. A. [3 ]
Lee, S. Y. [4 ]
Hochmair, M. J. [5 ]
Lee, S. H. [6 ]
Escriu, C. [7 ]
Lee, M. K. [8 ]
Migliorino, M. R. [9 ]
Lee, Y. C. [10 ]
Girard, N. [11 ]
Daoud, H. [12 ]
Marten, A. [12 ]
Miura, S. [13 ]
机构：
[1] Royal Marsden Natl Hlth Serv Fdn Trust, Lung Unit, London, England
[2] Inst Canc Res, London, England
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
[4] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea
[5] Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Vienna, Austria
[6] Kyung Hee Univ, Div Pulm & Crit Care Med, Dept Internal Med, Med Ctr,Sch Med, Seoul, South Korea
[7] Clatterbridge Canc Ctr, Wirral, Merseyside, England
[8] Pusan Natl Univ, Sch Med, Dept Internal Med, Busan, South Korea
[9] San Camillo Forlanini Hosp, Rome, Italy
[10] Chonbuk Natl Univ, Chonbuk Natl Univ Hosp, Res Inst Clin Med, Biomed Res Inst,Dept Internal Med,Med Sch, Jeonju, South Korea
[11] Inst Thorax Curie Montsouris, Inst Curie, Thorac Surg, Paris, France
[12] Boehringer Ingelheim Int Gmbh, Ingelheim, Germany
[13] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
EGFR mutation-positive NSCLC; osimertinib; afatinib;
D O I：
10.1016/j.jtho.2021.08.542
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P51.05
引用
下载
收藏
页码：S1120 / S1121
页数：2
相关论文
共 50 条
  • [21] Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation
    Luo, Yung-Hung
    Liu, Han
    Wampfler, Jason A.
    Tazelaar, Henry D.
    Li, Yalun
    Peikert, Tobias
    Liu, Dan
    Leventakos, Konstantinos
    Chen, Yuh-Min
    Yang, Yanan
    Chiou, Shih-Hwa
    Yang, Ping
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (08) : 2099 - 2114
  • [22] Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation
    Yung-Hung Luo
    Han Liu
    Jason A. Wampfler
    Henry D. Tazelaar
    Yalun Li
    Tobias Peikert
    Dan Liu
    Konstantinos Leventakos
    Yuh-Min Chen
    Yanan Yang
    Shih-Hwa Chiou
    Ping Yang
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2099 - 2114
  • [23] ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
    Zhou, Q.
    Zhang, H. -L.
    Jiang, L. -Y.
    Shi, Y. -K.
    Chen, Y.
    Yu, J. -M.
    Zhou, C. -C.
    He, Y.
    Hu, Y. -P.
    Liang, Z. -A.
    Pan, Y. -Y.
    Zhuo, W. -L.
    Song, Y.
    Wu, G.
    Chen, G. -Y.
    Lu, Y.
    Zhang, C. -Y.
    Zhang, C. -Y.
    Zhang, Y. -P.
    Chen, Y.
    Lu, S.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S429 - S430
  • [24] Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
    Zhao, Sha
    Li, Xuefei
    Zhao, Chao
    Jiang, Tao
    Jia, Yijun
    Shi, Jinpeng
    He, Yayi
    Li, Jiayu
    Zhou, Fei
    Gao, Guanghui
    Li, Wei
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    LUNG CANCER, 2019, 128 : 33 - 39
  • [25] Mechanisms of acquired resistance to osimertinib in advanced NSCLC with EGFR T790M mutation (LOGIK1607)
    Yamaguchi, Masafumi
    Osoegawa, Atsushi
    Nakamura, Tomomi
    Morinaga, Ryotaro
    Tanaka, Kentaro
    Kashiwabara, Kosuke
    Miura, Takashi
    Suetsugu, Takayuki
    Taguchi, Kenichi
    Nabeshima, Kazuki
    Kishimoto, Junji
    Sakai, Kazuko
    Nishio, Kazuto
    Sugio, Kenji
    CANCER SCIENCE, 2021, 112 : 567 - 567
  • [26] Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
    Zhang, X.
    Wu, Y-L.
    Chen, Y.
    Zhang, H.
    Wu, G.
    Lu, Y.
    Liang, Z.
    Hu, Y.
    Cheng, Y.
    Wang, J.
    Ying, J.
    Liu, W.
    Liang, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1537 - S1537
  • [27] Afatinib Followed by Osimertinib in Real-World Patients with EGFR Mutation-Positive Advanced NSCLC: The Giotag Study
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C.
    Soo, R.
    Yang, J. C.
    Gucalp, R.
    Halmos, B.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1045 - S1045
  • [28] Afatinib followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: A real-world study (GioTag)
    Hochmair, M. J.
    Morabito, A.
    Hao, D.
    Yang, C-T.
    Soo, R. A.
    Yang, J. C-H.
    Gucalp, R.
    Halmos, B.
    Wang, L.
    Golembesky, A.
    Maerten, A.
    Cufer, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [29] Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
    Cao, Y.
    Qiu, X.
    Xiao, G.
    Hao, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
    Cao, Yabing
    Qiu, Xibin
    Xiao, Guangli
    Hu, Hao
    Lin, Tongyu
    PLOS ONE, 2019, 14 (08):
12345